

# Proteic Biosciences Inc. Announces Name Change to DiaGen Ai Inc., the Appointment of a New CEO, New Website and Update

VANCOUVER, BC, CANADA, December 13, 2023 /EINPresswire.com/ -- Proteic Biosciences Inc. ("Proteic") founded in 2021 to advance its proprietary AI engine in protein design and drug discovery, announces the completion of its corporate rebrand and name change to DiaGen AI Inc. ("DiaGen" or the "Company") (the "Name Change"),

## Appointment of New CEO



In connection with the rebranding, DiaGen has hired former Proteic capital markets advisor, Brian D. Keane as Chief Executive Officer ("CEO") and Chairman to join its President, Paolo Lobo and the rest of the team to lead the Company's liquidity pathway and artificial intelligence ("AI") operations optimization. Brian brings almost 30 years of legal and capital markets experience, having worked at multiple law firms and several funds and investment organizations where he has participated in over \$3 billion in deal transactions. For the last decade he has specialized in c-suite, director, and capital market advisory roles for Canadian private and public companies and their crossover to USA and globally.

"Our team and shareholders are excited to have Brian join us to lead the Company as it enters its next phase, our rebrand to DiaGen AI appropriately showcases our focus as an AI company with the continued mission to making advancements in healthcare through the fusion of protein design, innovation, application, ("DIA") in addition to generative AI for drug discovery" Stated Paolo Lobo.

"I'm very grateful for this opportunity to be part of a team of experienced founders and scientists especially with our newly branded Company and its AI engine 'DIA' (design, innovate apply). Via this platform, we hope to continue to show the successful application of AI in protein design and drug discovery and ideally making a meaningful impact in the future of traditional medicine and healthcare," said Brian.

The Name Change as well as onboarding of Brian D. Keane was approved by the board of directors of the Company in accordance with the Company's governing corporate legislation, the Business Corporations Act (British Columbia), and the Company's constating documents.

## Corporate Updates

DiaGen AI is pleased to announce multiple milestones and advancements to update its shareholders and the community as we continue to evolve our proprietary AI engine, DIA, to build new proteins and peptides, advance our partnership program with small and medium enterprises in drug discovery, diagnostics, and vaccines to drive revenue and non-dilutive investment, and target strategic acquisitions and search for new talent.

## New Website

We are proud to announce the launch of our new website: [Diagen.ai](https://www.diagen.ai) and our multiple communication channels to help build our community via LinkedIn, X, and Instagram. Please visit [www.diagen.ai](https://www.diagen.ai) for more information and to join our community.

## New Team Members

### Appointment of Chief Operating Officer

In addition to our president, Paolo Lobo, who brings over a decade of experience in the biotech industry, protein biochemistry and business development, the Company has added Dr. Sara Ibrahim Omar as Chief Operating Officer and head of computation biology. Dr. Sara brings over 12 years' experience working as computational lead having worked on COVID-19 research at the University of Alberta and as a computational research scientist at SinoVeda Canada Inc. She was a former member of the Canadian Society for Chemistry, Cancer Research Institute of Northern Alberta, and Alberta DNA repair consortium. She has over a dozen publications in peer-reviewed journals and has presented in over 20 conferences and seminars.

### Frontier IP Group PLC. as Advisor

In early 2022, Frontier IP (LSE: FIPP) joined as a strategic advisor led by CEO Neil Crabb to assist in our corporate AI strategy in the field of drug discovery. Neil has led multiple organisations in the field of intellectual property and Artificial Intelligence including Oxford's Creative Destruction Lab and Frontiers collaboration with Exscientia (Nasdaq:EXAI)

### Creative Destruction Lab ("CDL"):

In summer of 2023, our team, led by Paolo and Dr. Sara successfully graduated from the Creative Destruction Lab. As participants in the computational health cohort in Seattle, Washington, Creative Destruction Lab employed a rigorous 8 month, objectives-based, validation process by a

selected group of entrepreneurs, angel investors, economists, and scientists that evaluated DiaGen (formerly known as Proteic Bioscience Inc.). Through various sessions of mentor evaluation and platform testing, our AI engine was evaluated on its progress as well as our teams coachability and our probability of success whereby we successfully graduated amongst dozens of peer reviewed companies.

For more information, please visit [www.diagen.ai](http://www.diagen.ai)

Or

Contact us:

Brian D. Keane

Chairman and CEO

Email: [ir@diagen.ai](mailto:ir@diagen.ai)

### Forward-Looking Statement Cautions

This press release contains certain "forward-looking statements" within the meaning of Canadian securities legislation, relating to the Company's plans and expectations. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "suggests," "indicate," "often," "target," "future," "likely," "pending," "potential," "goal," "objective," "prospective," and "possibly," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. Forward-looking statements in this news release include statements relating to: the Company's ability to make advancements in industry using its proprietary DEI technology; the Company's focus on the AI sector; the Company providing a return on investment for its shareholders; and the continued growth of the Company, viability of its DEI technology; general applicability of AI technology towards the healthcare sector, particularly drug discovery, diagnostics, and vaccines; the ability of the Company to find strategic acquisitions and consummate transactions to acquire such entities; and the ability of the Company to use its technology to make a meaningful impact on the healthcare industry.

The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements that the Company will not be able to raise sufficient funds to carry out its business plans, and the risk of political uncertainties and regulatory or legal changes that might interfere

with the Company's business and prospects.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to make advancements in industry using its proprietary DEI technology; the Company's expectation of growth of the AI sector as it applies to healthcare; the Company's ability to provide a return on investment for its shareholders; the continued growth of the Company; the viability of the Company's DEI technology; the continued applicability of AI technology within the healthcare sector, particularly drug discovery, diagnostics, and vaccines; the ability of the Company to find strategic acquisitions and consummate transactions to acquire such entities; and the ability of the Company to use its technology to make a meaningful impact on the healthcare industry.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.

Brian Keane  
Diagen Ai Inc.  
+1 201-736-3590  
ir@diagen.ai

Visit us on social media:

[Twitter](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/674896900>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.